ActivShield Light Adjustable Lens.
The RxSight Light Adjustable Lens (LAL) is now available in Australia – allowing an intraocular lens (IOL) to be adjusted to the patient after implantation.
RxSight – a United States-based ophthalmic medical technology corporation – said the LAL is the “first and only” intraocular lens that can be adjusted non-invasively after implantation, allowing refinement of refractive outcomes when a patient has healed.
The lens is composed of a photosensitive silicone material containing macromers that polymerise in response to precisely delivered ultraviolet light. Using the Light Delivery Device, spatially targeted light treatments induce controlled redistribution of these macromers, resulting in predictable changes in lens curvature and refractive power.1
Adjustments are performed in-office and can be delivered in 0.25 D increments to refine both spherical and cylindrical error, RxSight said.
Adjustments are performed in-office and can be delivered in 0.25 D increments to refine both spherical and cylindrical error
RxSight said the availability of the RxSight LAL in Australia introduces a postoperative approach to refractive optimisation. By enabling surgeons to modify lens power after surgery, the LAL “may reduce residual refractive error and enhance accuracy, particularly in eyes where preoperative calculations are less predictable, such as those with prior corneal refractive surgery”, RxSight said.
The company said clinical studies have demonstrated a high level of refractive precision with the LAL. In the Post Approval Study, 93.1% of eyes (N=309) achieved outcomes within ±0.50 diopters of target manifest refraction spherical equivalent (MRSE), and over 82.5% of eyes achieved uncorrected distance visual acuity of 20/20 or better, compared to 50.6% with a standard monofocal IOL.¹ These outcomes are consistent with the goal of improving refractive predictability in cataract surgery.
The LAL uses a monofocal, non-diffractive optic design and does not rely on light-splitting mechanisms to achieve its refractive effect. This may be a relevant consideration when evaluating visual quality, particularly in patients sensitive to dysphotopsia.
“Using postoperative adjustment, this technology flips the script and will be the first ever opportunity for cataract patients to test-drive and customise their vision,” RxSight said.
The Light Delivery Device corrects refractive error and dials in optimised vision.
Reference
- Food and Drug Administration, RxSight. P160055: Summary of Safety and Effectiveness Data. 2017. Available at: accessdata.fda.gov/cdrh_docs/pdf16/P160055B.pdf [accessed May 2026].
